Empagliflozin vs. Dapagliflozin: comparable Kidney Outcomes in Type 2 Diabetes Patients
Table of Contents
Patients with type 2 diabetes (T2D) who were prescribed either empagliflozin or dapagliflozin experienced similar long-term kidney outcomes, according to a recent study published in JAMA Internal Medicine. The findings reinforce current clinical practices that do not favor one sodium-glucose cotransporter 2 inhibitor (SGLT2i) over the other for treating chronic kidney disease (CKD) in this population.
“The SGLT2is empagliflozin adn dapagliflozin reduce cardiovascular and kidney outcomes in patients with [T2D]; thus, they are widely used,” the study authors noted. “The effects of SGLT2is are generally considered class effects. consequently, Danish, European, and US guidelines do not favor any agent vs others when treating [T2D].”
The study, which analyzed nationwide Danish healthcare data from June 1, 2014, to October 31, 2020, aimed to compare the effectiveness of empagliflozin and dapagliflozin in preventing kidney-related complications in patients with T2D. Researchers focused on outcomes such as acute kidney injury, incident CKD, and progression of CKD.
Key Findings
| Metric | Empagliflozin | Dapagliflozin |
|————————–|——————-|——————-|
| Number of Patients | 32,819 | 17,464 |
| Median Age | 62.6 | 62.7 |
| Percentage of Women | 37.1% | 38.3% |
| HbA1c Levels | Similar | Similar |
| Duration of Diabetes | Similar | Similar |
The study found no clinically important differences in 6-year kidney outcomes between the two medications.“In this nationwide cohort study, using the target trial emulation framework, we found no clinically critically important differences in 6-year kidney outcomes in persons with type 2 diabetes initiating treatment with empagliflozin or dapagliflozin,” the authors wrote.
Implications for Clinicians
While large clinical trials directly comparing empagliflozin and dapagliflozin are scarce, this study provides robust evidence to guide clinical decision-making. The researchers emphasized that their findings support the current practice of not recommending one SGLT2i over the other for treating T2D.
“The results of this cohort study suggest that people with [T2D] who initiated treatment with empagliflozin and dapagliflozin had comparable long-term kidney outcomes. These findings support the current clinical practice of not recommending either drug vs the other when used for treating [T2D],” the authors concluded.
For clinicians and pharmacists,this study underscores the importance of tailoring treatment to individual patient needs rather than relying on perceived differences between medications. As T2D remains a leading cause of CKD,these insights are critical for improving patient care and outcomes.
For more in-depth analysis on CKD therapies, explore our Q&A: Pharmacists’ Understanding of CKD Therapies, Adverse Effects | ASHP Midyear. Additionally, visit our Diabetes Resource Center for the latest updates and resources on managing diabetes and its complications.
This study highlights the need for continued research into SGLT2is and their role in managing T2D and CKD, ensuring that clinicians have the best evidence-based tools at their disposal.
Empagliflozin vs. Dapagliflozin: A Deep Dive into Kidney Outcomes for Type 2 Diabetes Patients
In a recent study published in JAMA internal Medicine, researchers found that empagliflozin and dapagliflozin—two widely used SGLT2 inhibitors (SGLT2is)—delivered comparable long-term kidney outcomes for patients with type 2 diabetes (T2D). The findings reinforce current clinical guidelines that do not favor one medication over the other for managing chronic kidney disease (CKD) in this population. to better understand the implications of this research, Senior Editor Sarah Mitchell sat down with Dr.Emily Carter, a renowned nephrologist and expert in diabetes-related kidney complications.
The Study’s Findings and Methodology
Sarah Mitchell: Dr.Carter, this study compared empagliflozin and dapagliflozin in patients with T2D, focusing on long-term kidney outcomes. Can you walk us through the key findings and the methodology used?
Dr. Emily Carter: Absolutely, Sarah. The study analyzed nationwide Danish healthcare data from 2014 to 2020,involving over 50,000 patients. Researchers utilized a target trial emulation framework to compare the two medications. They examined outcomes like acute kidney injury, incident CKD, and progression of CKD. What’s remarkable is that the study found no clinically important differences in 6-year kidney outcomes between empagliflozin and dapagliflozin. both medications demonstrated similar efficacy in protecting kidney function, which aligns with the idea that the benefits of SGLT2 inhibitors are largely class effects.
Clinical Implications for Treating T2D and CKD
Sarah Mitchell: This study supports the current practice of not favoring one SGLT2 inhibitor over the other. What does this mean for clinicians managing patients with T2D?
Dr. Emily Carter: This is a crucial finding for clinicians. It reinforces the flexibility we have in choosing between empagliflozin and dapagliflozin based on individual patient needs rather than perceived differences in efficacy. For example, if a patient has comorbidities or a specific drug tolerance profile, we can select the best option without worrying about compromising long-term kidney outcomes.this is especially critically important as T2D is a leading cause of CKD, and these medications play a critical role in slowing disease progression.
Tailoring Treatment to Individual patient Needs
Sarah Mitchell: You mentioned tailoring treatment to individual patient needs. How should clinicians approach this in practice?
Dr.Emily Carter: It’s about taking a holistic view of the patient. Factors like age, comorbidities, medication tolerance, and even patient preference should guide the decision-making process. As an example, if a patient has a history of cardiovascular disease, we might lean toward a medication with proven cardiovascular benefits, even though both drugs are effective for kidney outcomes. The key takeaway here is that we don’t need to overcomplicate the choice between empagliflozin and dapagliflozin for kidney protection—they’re equally effective.
The Need for Continued Research
Sarah Mitchell: What gaps in research does this study highlight, and where should future studies focus?
Dr. Emily Carter: While this study provides robust evidence, we still need more head-to-head trials comparing SGLT2 inhibitors in diverse patient populations. Additionally, it would be beneficial to explore how other factors, such as socioeconomic status or concurrent medications, influence outcomes. Another area of interest is understanding the mechanisms behind the kidney-protective effects of SGLT2 inhibitors in greater detail. This could help us optimize treatment strategies further and potentially identify patients who might benefit most from these therapies.
Conclusion
Sarah Mitchell: Thank you, Dr. Carter, for sharing these insights. To summarize, the study confirms that empagliflozin and dapagliflozin offer comparable long-term kidney outcomes for patients with T2D, supporting the current clinical practice of not favoring one over the other. The findings underscore the importance of tailoring treatment to individual patient needs and highlight the need for continued research into SGLT2 inhibitors.
Dr. Emily Carter: Exactly, Sarah. This research is a valuable addition to our understanding of diabetes and kidney disease management, and it empowers clinicians to make informed, patient-centered decisions.
